GuideAI Health vs Nucs AI (2026)
Two narrow imaging companies, each built around one disease, and neither competes with the other clinically. GuideAI's VascularAssist Occlusion Triage, cleared in June 2026 (K260729), reads adult CT angiography and notifies the radiologist of patterns consistent with total occlusion from the aorta to the popliteal arteries; the radiologist still reads every study. Its pivotal study of 317 cases reported sensitivity of 91.5 percent and specificity of 90.1 percent. Nucs AI builds tools for PSMA PET/CT in prostate cancer: lesion detection and staging, response prediction and tracking over time, with a physician reviewing and editing every case. Its products are investigational, not FDA cleared or CE marked. A vascular service looks at GuideAI; a prostate cancer or theranostics service looks at Nucs, knowing it is not yet cleared.
- A cleared triage product: VascularAssist Occlusion Triage was cleared in June 2026 for total occlusion on adult CT angiography, notifying the radiologist through the PACS.
- Performance with a denominator: the pivotal study reports sensitivity of 91.5 percent and specificity of 90.1 percent on 317 cases.
- Patient data handling stated: a gateway at the hospital removes identifiers before cloud analysis, and an on premises option is offered.
- The whole PSMA pathway: DeepPSMA detects lesions, stages and quantifies tumor burden, SelectPSMA predicts response to radioligand therapy, and TrackPSMA compares scans over time.
- A physician reviews every case: findings are reviewed and edited before a report is generated, and the company says more than half need no edits.
- Research and pharma use today: it sells to clinicians, pharmaceutical companies and researchers while FDA clearance and CE marking are described as in progress.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. GuideAI Health and Nucs AI are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | GuideAI Health | Nucs AI |
|---|---|---|
| Primary category | Radiology & Imaging AI | Radiology & Imaging AI |
| Founded | 2023 | 2024 |
| Headquarters | Boston, Massachusetts, United States | New York, New York, United States |
| Website | guideaihealth.com | nucs.ai |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Company founded by interventional radiologists to find peripheral arterial disease in imaging already taken. Its one product in market, VascularAssist Occlusion Triage (VAOT), was cleared through FDA 510(k) K260729 in June 2026 as Class II triage and notification software. It reads adult CT angiography and notifies the radiologist through the PACS when it finds a pattern consistent with total occlusion between the aorta and the popliteal arteries.
Source: AI Health Index, September 2026
New York company, founded in 2024, building deep learning tools for PSMA PET/CT in prostate cancer and theranostics. DeepPSMA detects lesions, assigns TNM stage and quantifies whole body tumor burden; SelectPSMA predicts response to PSMA targeted radioligand therapy; TrackPSMA compares scans over time to evaluate treatment response.
Source: AI Health Index, September 2026
Questions buyers ask
How do GuideAI Health and Nucs AI work with the EHR?
For GuideAI Health, a gateway acts as a PACS listener and receives a copy of each CT angiography study. The result comes back as a DICOM Secondary Capture carrying the preview image, which the PACS attaches to the original study and uses to notify radiologists.
With Nucs AI, results come back as a structured, shareable report with staging, and research users can export structured data as CSV. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 27, 2026. No vendor pays for placement.
How do GuideAI Health and Nucs AI handle patient data?
The K260729 summary says a gateway at the hospital takes a copy of each CT angiography study, de-identifies it, and only then sends it to the GuideAI cloud. What comes back is one axial preview slice, and the link to the patient is restored inside the hospital.
For Nucs AI, data is stored in encrypted form and access is limited to staff who need it, with an access log. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 27, 2026. No vendor pays for placement.
Which settings and specialties do GuideAI Health and Nucs AI cover?
With GuideAI Health, the validation covers total occlusion only, and only for triage. The website sells into five channels: teleradiology through vRad, academic centers, community hospitals and specialty practices, primary care population health, and executive health.
In Nucs AI's case, the products are investigational and not for clinical diagnostic use. Nothing published yet validates the stated coverage with counts: the accuracy figures come from internal studies with no populations described, and the any tracer claim has no results by tracer. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 27, 2026. No vendor pays for placement.
What evidence is published for GuideAI Health and Nucs AI?
For GuideAI Health, the set was enriched for aortic occlusions (21 cases).
With Nucs AI, the DeepPSMA page cites internal studies for 92 percent accuracy in detecting PSMA positive lesions, 87 percent in TNM staging and 99 percent in tumor quantification. For response prediction it cites a 94 percent negative predictive value for identifying non responders, and 4.56 times the risk of progression and 2.1 times the risk of death for predicted non responders. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 27, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
GuideAI's cleared indication covers total occlusion only, not stenosis, and its plaque, carotid, coronary and Elevate modules are labeled not cleared; the site's "up to 95%" sensitivity does not match the filing. Nucs AI's products are not for clinical diagnostic use, and its figures come from internal studies without case counts. Neither vendor publishes a security certification or a price.